Decheng Capital

Decheng Capital LLC is a private equity and venture capital firm established in 2012, with its headquarters in Menlo Park, California, and additional offices in Shanghai, China, and New York, New York. The firm focuses on early-stage and growth capital investments primarily in the life sciences and healthcare sectors, including life science tools, biopharmaceuticals, medical devices, diagnostics, digital health technologies, and agricultural biotechnology. Decheng Capital aims to leverage its expertise and strategic support to help innovative companies in these fields thrive, particularly in China. With over $1 billion in capital under management, the firm is well-positioned to capitalize on opportunities arising from the rapid growth of the healthcare industry and advancements in life science research.

Susan Y. Chen

Associate

Peter Colabuono

Principal

MIN CUI, PH.D

Managing Director

Xiangmin Cui

MP

Aaron Li

Vice President

Yang Lu

Vice President

Dayton Misfeldt

Partner

Nick Pliam

Partner

Tony Tong

Principal

Victor E. Tong JR.

Partner

Qiang Xu

Partner

Wei Xu

Partner

Y. Katherine Xu

Partner

Daniel L. Zabrowski

Venture Partner

68 past transactions

ACELYRIN

Series C in 2022
ACELYRIN is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of promising drug candidates and by leveraging its expertise to rapidly advance these medicines to patients.

Watchmaker Genomics

Series A in 2022
Watchmaker Genomics, Inc. operates as a biotechnology company that engages in research and development of genomes. It offers protein engineering with enzyme manufacturing. Its platform offers solutions to improve genomic experiment, assay and workflow, and scalable supply-chain solutions. Watchmaker Genomics, Inc. was formerly known as Alpha Catalyst Genomics, Inc. and changed its name to Watchmaker Genomics, Inc. in July 2019. The company was incorporated in 2018 and is based in Boulder, Colorado.

Upstream Bio

Series A in 2022
Upstream Bio is a clinical-stage biotechnology company established in 2004 and headquartered in the United States. The company specializes in developing antibody therapies aimed at treating inflammatory diseases, with a primary focus on severe respiratory disorders, particularly severe asthma. Upstream Bio is advancing its lead candidate, verekitug, an antagonist that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine known to play a significant role in driving inflammatory responses. The approach of targeting TSLP positions Upstream Bio to address various immune-mediated conditions by intervening at a crucial point in the signaling pathways involved in inflammation.

Mirvie

Series B in 2022
Mirvie is a biotech company that creates precise, actionable, and non-invasive tests for maternal-fetal health. The company delivers insights to moms and families to make pregnancy safe. It was founded in 2018 by Maneesh Jain and is headquartered in South San Francisco, California, United States.

Nalu Medical

Venture Round in 2022
Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people. The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California.

ImmPACT Bio

Series B in 2022
ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues.

Kind Pharmaceutical

Series B in 2021
Kind Pharmaceutical is a clinical-stage biopharmaceutical company that focuses on the discovery and development of anemia drugs. The company was founded in 2013 and is headquartered in Redwood City, California, United States.

ACELYRIN

Series B in 2021
ACELYRIN is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of promising drug candidates and by leveraging its expertise to rapidly advance these medicines to patients.
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the discovery and development of protein-based immunotherapies aimed at treating cancer, autoimmune, and inflammatory disorders. The company's lead programs include ALPN-101, an antagonist targeting the inducible T cell costimulator and CD28 pathways for autoimmune and inflammatory diseases, and ALPN-202, which combines programmed cell death protein ligand 1 and cytotoxic T-lymphocyte associated protein 4 antagonism with PD-L1 dependent CD28 costimulation for cancer treatment. Additionally, Alpine has a collaboration with Kite Pharma, Inc. to develop immunotherapies that target the immune synapse for cancer therapy. The company utilizes a proprietary platform to transform native immune system proteins into innovative, multi-targeted therapeutics.

Mammoth Biosciences

Series D in 2021
Mammoth Biosciences, Inc. is a biotechnology company based in South San Francisco, California, founded in 2017. It specializes in developing advanced CRISPR solutions, including its proprietary DETECTR technology, which allows for the detection of specific nucleic acids in samples, aiding in diagnostics for various conditions such as bacterial infections, cancer, and viral infections. The company focuses on democratizing disease detection through accessible point-of-care tests that can simultaneously identify multiple health issues. Additionally, Mammoth offers CRISPR-Cas systems for genome editing, targeting therapeutic applications in immuno-oncology, autoimmune diseases, and liver diseases. Its innovative solutions are utilized across diverse sectors, including healthcare, agriculture, environmental monitoring, and biodefense. Co-founded by CRISPR pioneer Jennifer Doudna, Mammoth Biosciences is supported by notable institutional and individual investors, reflecting its commitment to harnessing CRISPR technology for significant advancements in life sciences.

Shape Therapeutics

Series B in 2021
Shape Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, focused on RNA-editing gene therapy for various medical conditions, including neurodegenerative disorders, oncology, metabolic diseases, and rare genetic diseases. Founded in 2018, the company has developed RNAfix technology, which utilizes the natural cellular machinery of the human body to edit RNA. This approach significantly reduces the risks of immunogenicity, cellular toxicity, and off-target DNA editing that are often associated with traditional gene-editing methods, such as CRISPR. Shape Therapeutics aims to create next-generation gene therapies that provide effective and safer treatment options for patients with challenging medical conditions.

Shape Therapeutics

Series B in 2021
Shape Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, focused on RNA-editing gene therapy for various medical conditions, including neurodegenerative disorders, oncology, metabolic diseases, and rare genetic diseases. Founded in 2018, the company has developed RNAfix technology, which utilizes the natural cellular machinery of the human body to edit RNA. This approach significantly reduces the risks of immunogenicity, cellular toxicity, and off-target DNA editing that are often associated with traditional gene-editing methods, such as CRISPR. Shape Therapeutics aims to create next-generation gene therapies that provide effective and safer treatment options for patients with challenging medical conditions.

GRIT Biotechnology

Series A in 2021
GRIT Biotechnology is engaged in research and development of tumor infiltration lymphocytes immunotherapy for curing solid tumors. The company is based in Shanghai, China.

Adela

Series A in 2021
Adela is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a routine blood test.

Cue

Private Equity Round in 2021
Cue Health Inc. is a San Diego-based healthcare technology company that specializes in the development and manufacturing of medical diagnostic products designed for easy use in various settings, including clinics, schools, and senior living facilities. The company offers the Cue Health Monitoring System, a connected diagnostic platform that allows healthcare professionals to access essential health information through self-serve tests, providing results directly to mobile devices. Additionally, Cue Health provides test cartridges and a consumer software application that features a personalized health dashboard, storing test results and enabling connections to on-demand telemedicine and prescription services. The platform also supports healthcare professionals in managing patient test histories and facilitating follow-up consultations, including telemedicine options. Founded in 2010, Cue Health aims to empower individuals with the ability to track key health indicators, such as inflammation, vitamin D levels, fertility, influenza, and testosterone, at the molecular level from the comfort of their homes.

Cellares

Series B in 2021
Cellares Corporation develops cell therapy for the treatment of cancer. The company develops solution to overcome limitation of manufacturing to make cell therapies for patients. Cellares Corporation was founded in 2019 and is based in South San Francisco, California.

PackGene Biotech

Series C in 2021
PackGene Biotech, LLC develops viral vectors for gene therapies. The company offers adeno-associated virus (AAV) vector cloning/packaging services. PackGene Biotech, LLC is based in the United States.

Bioheng

Series B in 2021
Nanjing Bioheng Biotech Co., Ltd., a clinical biopharmaceutical and a biotechnology company, develops immunotherapy and gene therapy for treating cancer and various diseases. The company offers precision and scarless gene editing and CART therapy. It also develops a production platform for manufacturing plasmid, virus, and cells. The company was founded in 2017 and is based in Nanjing, China.

EpimAb Biotherapeutics

Series C in 2021
EpimAb Biotherapeutics, Inc operates as a biopharmaceutical research and development company develops novel bispecific antibody therapeutics for immuno-oncology and other areas of patients. Its Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform generates bispecific molecules with antibody-like properties. The company is based in Shanghai, China.

Neurelis

Series D in 2021
Neurelis is a specialty pharmaceutical company based in Encinitas, California, that focuses on the licensing, development, and commercialization of product candidates for epilepsy and the broader central nervous system (CNS) market. Established in 2007, Neurelis aims to address unmet medical needs through its differentiated approach and the application of novel technologies, which are intended to enhance therapeutic benefits and improve patient care.

Equillium

Post in 2021
Equillium, Inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was founded in 2017 and is headquartered in La Jolla, California.

Ark Biosciences

Series C in 2021
Ark Biosciences Inc., a biopharmaceutical company, discovers and develops therapeutics to address unmet medical need in the areas of respiratory viral infection and viral hepatitis for worldwide markets. Its products include AK0701 for Chronic obstructive pulmonary disease (COPD), AK0529 for Respiratory syncytial virus (RSV), AK0612 for Influenza, and AK0705 and AK0706 for Hepatitis B. The company was founded in 2013 and is based in Shanghai, China.

LevitasBio

Series B in 2021
Levitas, Inc. is redefining cellular analytics with its novel platform magnetic levitation technology. Our disruptive technology overcomes the current technological limitation of cellular analysis by providing label free, simple, and universal methods of analysis. We are developing our platform across a wide range of cellular applications, including therapeutic, diagnostic, and research applications, which will enable a wide range of novel research and precision health.

Encodia

Series C in 2020
Encodia, Inc. engages in proteomics research and creates scalable and parallelized approaches to protein analysis. The company was founded in 2015 and is based in San Diego, California.

GRIT Biotechnology

Series A in 2020
GRIT Biotechnology is engaged in research and development of tumor infiltration lymphocytes immunotherapy for curing solid tumors. The company is based in Shanghai, China.

PackGene Biotech

Series B in 2020
PackGene Biotech, LLC develops viral vectors for gene therapies. The company offers adeno-associated virus (AAV) vector cloning/packaging services. PackGene Biotech, LLC is based in the United States.

GeneDx

Series C in 2020
Sema4 is a patient-centered predictive health company dedicated to advancing the diagnosis, treatment, and prevention of disease. With their innovative Sema4 Health Intelligence Platform, they’re using advanced network analysis to build better models of human health and deliver personalized insights for patients.

Polares Medical

Series B in 2020
Polares Medical S.A. is a medical device company based in Ecublens, Switzerland, with an additional office in Palo Alto, California. The company specializes in developing innovative solutions for patients suffering from mitral valve regurgitation. Its flagship product features a unique trans-catheter mitral valve system that facilitates the replacement of the posterior leaflet with a prosthetic leaflet. This design enables physicians to perform hemi-replacements of the mitral valve, improving coaptation with the native anterior leaflet and offering a less invasive treatment option for patients.

Cue

Series C in 2020
Cue Health Inc. is a San Diego-based healthcare technology company that specializes in the development and manufacturing of medical diagnostic products designed for easy use in various settings, including clinics, schools, and senior living facilities. The company offers the Cue Health Monitoring System, a connected diagnostic platform that allows healthcare professionals to access essential health information through self-serve tests, providing results directly to mobile devices. Additionally, Cue Health provides test cartridges and a consumer software application that features a personalized health dashboard, storing test results and enabling connections to on-demand telemedicine and prescription services. The platform also supports healthcare professionals in managing patient test histories and facilitating follow-up consultations, including telemedicine options. Founded in 2010, Cue Health aims to empower individuals with the ability to track key health indicators, such as inflammation, vitamin D levels, fertility, influenza, and testosterone, at the molecular level from the comfort of their homes.

Cue

Series C in 2020
Cue Health Inc. is a San Diego-based healthcare technology company that specializes in the development and manufacturing of medical diagnostic products designed for easy use in various settings, including clinics, schools, and senior living facilities. The company offers the Cue Health Monitoring System, a connected diagnostic platform that allows healthcare professionals to access essential health information through self-serve tests, providing results directly to mobile devices. Additionally, Cue Health provides test cartridges and a consumer software application that features a personalized health dashboard, storing test results and enabling connections to on-demand telemedicine and prescription services. The platform also supports healthcare professionals in managing patient test histories and facilitating follow-up consultations, including telemedicine options. Founded in 2010, Cue Health aims to empower individuals with the ability to track key health indicators, such as inflammation, vitamin D levels, fertility, influenza, and testosterone, at the molecular level from the comfort of their homes.

Checkmate Pharmaceuticals

Series C in 2020
Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Everest Medicines

Series C in 2020
Everest Medicines Limited, a clinical-stage biopharmaceutical company, focuses on licensing, developing, and commercializing therapies for addressing critical unmet medical needs in Greater China and other Asia Pacific markets. It has a portfolio of eight clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal disease, and infectious diseases. The company was founded in 2017 and is headquartered in Shanghai, China.

LYNK Pharmaceuticals

Series A in 2020
LYNK Pharmaceuticals is a biotechnology company based in Hangzhou, China, specializing in the development of small molecule drugs aimed at treating tumors and autoimmune diseases. Founded in 2017, the company focuses on the discovery and development of innovative medicines in the fields of oncology, immunology, and inflammatory diseases. Its business operations include new drug research, sales, and activities related to patent authorization and transfer.

Apexigen

Series C in 2020
Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for the treatment of cancer. The company develops a pipeline of therapies and product candidates, including APX005M and APX201 for immuno-oncology, APX003/BD0801 and TRK-950 for oncology, APX001/SSS07 for inflammation, and APX003/TK001 for ocular diseases. It also develops APXiMAB platform, which enables discovery of antibodies for novel immune system targets. The company was founded in 2010 and is based in San Carlos, California.

Mammoth Biosciences

Series B in 2020
Mammoth Biosciences, Inc. is a biotechnology company based in South San Francisco, California, founded in 2017. It specializes in developing advanced CRISPR solutions, including its proprietary DETECTR technology, which allows for the detection of specific nucleic acids in samples, aiding in diagnostics for various conditions such as bacterial infections, cancer, and viral infections. The company focuses on democratizing disease detection through accessible point-of-care tests that can simultaneously identify multiple health issues. Additionally, Mammoth offers CRISPR-Cas systems for genome editing, targeting therapeutic applications in immuno-oncology, autoimmune diseases, and liver diseases. Its innovative solutions are utilized across diverse sectors, including healthcare, agriculture, environmental monitoring, and biodefense. Co-founded by CRISPR pioneer Jennifer Doudna, Mammoth Biosciences is supported by notable institutional and individual investors, reflecting its commitment to harnessing CRISPR technology for significant advancements in life sciences.

ReadCoor

Series B in 2020
ReadCoor, Inc. develops and commercializes a panomic spatial sequencing platform for researchers, clinicians, pharmaceutical and diagnostics companies, and patients worldwide. It offers FISSEQ, a platform that enables integration of high throughput sequencing, morphometric analysis, cellular location, and three-dimensional spatial imaging. The company’s platform also enables researchers to perform RNA-Seq while preserving sample morphology and simultaneously providing cellular location and spatial image data. ReadCoor, Inc. was incorporated in 2016 and is based in Cambridge, Massachusetts. As of October 13, 2020, ReadCoor, Inc. operates as a subsidiary of 10x Genomics, Inc.

Omniome

Series C in 2020
Omniome, Inc. is a biotechnology company based in San Diego, California, established in 2013. It specializes in developing a proprietary DNA sequencing platform that aims to deliver high accuracy in sequencing results. The company employs its Sequencing By Binding technology, which enhances nucleotide and DNA matching by utilizing the natural matching capabilities of polymerase. This innovative approach not only provides precise and rapid results but also offers a cost-effective solution, which has the potential to significantly advance cancer diagnostics. Omniome is backed by prominent life sciences venture investors and is focused on becoming a trusted leader in the field of clinical sequencing.

KeChow Pharma

Series C in 2019
Shanghai Kechow Pharma, Inc. is a biopharmaceutical company established in 2014 and headquartered in Shanghai, China. The company specializes in the discovery of targeted small molecule drugs, aiming to develop innovative therapies that improve upon existing treatments. KeChow Pharma collaborates with various partners to co-develop its drug candidates, emphasizing a commitment to advancing healthcare through novel therapeutic solutions.

Zepto

Venture Round in 2019
Mynosys Cellular Devices is a global ophthalmic technology company dedicated to providing surgeons with innovative solutions that enable procedural excellence

GeneDx

Series B in 2019
Sema4 is a patient-centered predictive health company dedicated to advancing the diagnosis, treatment, and prevention of disease. With their innovative Sema4 Health Intelligence Platform, they’re using advanced network analysis to build better models of human health and deliver personalized insights for patients.

Hummingbird Bioscience

Series A in 2019
Hummingbird Bioscience Pte. Ltd. is a biotechnology company based in Singapore, specializing in the development of antibody-based therapeutics for cancer. Founded in 2014, it leverages advances in systems biology and a proprietary rational antibody discovery platform to create innovative biotherapeutics. The company focuses on a diverse pipeline of drug candidates, which includes lead assets such as HMBD-001, an anti-HER3 antibody, and HMBD-002, an anti-VISTA antibody, both aimed at addressing significant unmet medical needs in oncology. Hummingbird Bioscience has established strategic collaborations with notable organizations such as Cancer Research UK and Amgen, and it has received a product development grant from the Cancer Prevention and Research Institute of Texas. The company's goal is to enhance treatment options for patients facing challenging cancer diagnoses through its cutting-edge research and development efforts.

AnHeart Therapeutics

Series A in 2019
AnHeart Therapeutics is a clinical-stage biotechnology company based in Hangzhou, China, founded in 2018. The company specializes in the discovery and development of innovative pharmaceutical products aimed at enhancing human health and quality of life. AnHeart Therapeutics is particularly focused on the acquisition and commercialization of novel therapeutics. Its lead research product, AB-106, is an oral small molecule inhibitor that selectively targets ROS1 and NTRK, showcasing the company's commitment to advancing treatments for serious medical conditions.

Baoyuan Biomedical

Series A in 2019
Baoyuan Biomedical is a clinical stage company focused on acquiring, developing and commercializing innovative drugs that improve human health and quality of life, and is committed to innovative drug development that does not meet clinical needs. Its main research product, AB-106, is an oral, highly selective ROS1/NTRK small molecule inhibitor.

Bioheng

Series A in 2019
Nanjing Bioheng Biotech Co., Ltd., a clinical biopharmaceutical and a biotechnology company, develops immunotherapy and gene therapy for treating cancer and various diseases. The company offers precision and scarless gene editing and CART therapy. It also develops a production platform for manufacturing plasmid, virus, and cells. The company was founded in 2017 and is based in Nanjing, China.
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the discovery and development of protein-based immunotherapies aimed at treating cancer, autoimmune, and inflammatory disorders. The company's lead programs include ALPN-101, an antagonist targeting the inducible T cell costimulator and CD28 pathways for autoimmune and inflammatory diseases, and ALPN-202, which combines programmed cell death protein ligand 1 and cytotoxic T-lymphocyte associated protein 4 antagonism with PD-L1 dependent CD28 costimulation for cancer treatment. Additionally, Alpine has a collaboration with Kite Pharma, Inc. to develop immunotherapies that target the immune synapse for cancer therapy. The company utilizes a proprietary platform to transform native immune system proteins into innovative, multi-targeted therapeutics.

Checkmate Pharmaceuticals

Series C in 2018
Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Terns Pharmaceuticals

Series B in 2018
Terns Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing molecularly targeted, oral small-molecule drugs aimed at treating cancer and liver diseases. Founded in 2017 and headquartered in Foster City, California, with additional offices in Shanghai, China, Terns leverages its expertise in disease biology and medicinal chemistry to advance its drug pipeline. Notable products include TERN-101, a potent farnesoid X receptor agonist, and TERN-201, a semicarbazide-sensitive amine oxidase inhibitor. The company emphasizes a capital-efficient drug discovery model and has extensive clinical development capabilities in China, striving to bring innovative therapeutic candidates to address significant unmet medical needs both locally and globally.

VelosBio

Series A in 2018
VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat hematological cancers and solid tumors. The company specializes in therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), a cell-surface protein commonly found in various tumors but absent in normal tissues, making it a promising target for cancer treatment. Its lead product, VLS-101, is designed as a ROR1-directed ADC aimed at patients with both hematologic and solid tumor malignancies. Founded in 2017, VelosBio has demonstrated positive preclinical results for its ROR1-directed therapeutics, paving the way for potential use in monotherapy or in combination with other treatments across a wide range of cancers. As of late 2020, VelosBio operates as a subsidiary of Merck & Co., Inc.

Apexigen

Series B in 2018
Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for the treatment of cancer. The company develops a pipeline of therapies and product candidates, including APX005M and APX201 for immuno-oncology, APX003/BD0801 and TRK-950 for oncology, APX001/SSS07 for inflammation, and APX003/TK001 for ocular diseases. It also develops APXiMAB platform, which enables discovery of antibodies for novel immune system targets. The company was founded in 2010 and is based in San Carlos, California.

IMPACT Therapeutics

Series C in 2018
IMPACT Therapeutics, Inc. is a Shanghai-based biotechnology company focused on discovering, developing, and commercializing therapeutics for cancer and other severe diseases. Founded in 2009, the company is engaged in several innovative research and development projects, including the development of PARP inhibitors, Wee1 inhibitors, and other novel DNA damage response agents, as well as Hedgehog pathway inhibitors. IMPACT Therapeutics aims to create best-in-class drugs with independent intellectual property rights. The company's management team brings over four decades of combined experience in drug development and management, with expertise in pharmacology and biology, positioning the firm to advance its therapeutic offerings effectively.

Omniome

Series B in 2018
Omniome, Inc. is a biotechnology company based in San Diego, California, established in 2013. It specializes in developing a proprietary DNA sequencing platform that aims to deliver high accuracy in sequencing results. The company employs its Sequencing By Binding technology, which enhances nucleotide and DNA matching by utilizing the natural matching capabilities of polymerase. This innovative approach not only provides precise and rapid results but also offers a cost-effective solution, which has the potential to significantly advance cancer diagnostics. Omniome is backed by prominent life sciences venture investors and is focused on becoming a trusted leader in the field of clinical sequencing.

Polares Medical

Series A in 2018
Polares Medical S.A. is a medical device company based in Ecublens, Switzerland, with an additional office in Palo Alto, California. The company specializes in developing innovative solutions for patients suffering from mitral valve regurgitation. Its flagship product features a unique trans-catheter mitral valve system that facilitates the replacement of the posterior leaflet with a prosthetic leaflet. This design enables physicians to perform hemi-replacements of the mitral valve, improving coaptation with the native anterior leaflet and offering a less invasive treatment option for patients.

Mindstrong Inc.

Series B in 2018
Mindstrong Inc., operating as Mindstrong Health, focuses on remote patient monitoring and mental health symptom assessment through its innovative application. The platform utilizes AI-powered digital biomarker technology to enable users to monitor their mental health symptoms continuously and objectively. Mindstrong offers a range of services, including cognitive behavioral therapy, crisis management, and psychoeducation, delivered through structured messaging sessions. The company develops comprehensive care pathways that integrate passively collected data on cognitive function and mood, enhancing patient engagement through telehealth solutions. Founded in 2013 and based in Mountain View, California, Mindstrong collaborates with various stakeholders, including pharmaceutical companies, healthcare providers, and academic institutions, to advance medical innovation and improve healthcare delivery.

ARMO BioSciences

Series C in 2017
ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics. The company is based in Redwood City, California.

LevitasBio

Venture Round in 2017
Levitas, Inc. is redefining cellular analytics with its novel platform magnetic levitation technology. Our disruptive technology overcomes the current technological limitation of cellular analysis by providing label free, simple, and universal methods of analysis. We are developing our platform across a wide range of cellular applications, including therapeutic, diagnostic, and research applications, which will enable a wide range of novel research and precision health.

Aadi Bioscience

Series A in 2017
Aadi Bioscience, Inc. is a clinical stage biopharmaceutical company based in Pacific Palisades, California, founded by Dr. Neil Desai in 2011. The company focuses on the development of a potentially best-in-class mTOR inhibitor, specifically ABI-009, aimed at treating patients with oncology, cardiovascular, and metabolic diseases. Aadi Bioscience is dedicated to addressing unmet medical needs through its innovative therapeutic approaches in these areas.

EpimAb Biotherapeutics

Series A in 2017
EpimAb Biotherapeutics, Inc operates as a biopharmaceutical research and development company develops novel bispecific antibody therapeutics for immuno-oncology and other areas of patients. Its Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform generates bispecific molecules with antibody-like properties. The company is based in Shanghai, China.

Cirina

Series A in 2016
Cirina is developing innovative blood-plasma tests to detect deadly diseases at their earliest stages when curative treatments are most viable. The company is driven by the passion and life-long work of Co-founder and plasma nucleic acid pioneer, Dennis Lo, the first scientist to discover the presence of fetal DNA in a pregnant mother’s blood-plasma. Headquartered in South San Francisco, Calif., Cirina is currently actively recruiting top scientific and business talent to join its quest to detect devastating diseases like cancer at their earliest stages and empower people to take action. For more information, please visit http://cirinalabs.com.

ReadCoor

Series A in 2016
ReadCoor, Inc. develops and commercializes a panomic spatial sequencing platform for researchers, clinicians, pharmaceutical and diagnostics companies, and patients worldwide. It offers FISSEQ, a platform that enables integration of high throughput sequencing, morphometric analysis, cellular location, and three-dimensional spatial imaging. The company’s platform also enables researchers to perform RNA-Seq while preserving sample morphology and simultaneously providing cellular location and spatial image data. ReadCoor, Inc. was incorporated in 2016 and is based in Cambridge, Massachusetts. As of October 13, 2020, ReadCoor, Inc. operates as a subsidiary of 10x Genomics, Inc.

SentreHEART

Series D in 2016
SentreHEART, Inc., based in Redwood City, California, is a privately held medical device company that manufacturers the LARIAT Suture Delivery Device for remote delivery of a pre-tied suture loop. Innovation in catheter and suture delivery technology enables physicians to remotely deliver a 40mm pre-tied suture loop for immediate and complete soft tissue closure through access as small as 4.3mm and with no metal, clips or fabrics left behind. Regulatory clearance for soft tissue ligation and approximation has been received in the US, Europe, and Canada.

AccuraGen Inc.

Series B in 2016
We have developed a high-sensitivity next-generation sequencing-based system for the the detection of cancer mutations in miniscule concentrations of circulating cell-free DNA (cfDNA) in blood. Our technology addresses the significant barriers associated with harnessing the information contained in cfDNA by combining our proprietary techniques in molecular biology and computational algorithm for error suppression. With our technology, nanogram quantities of highly-fragmented cfDNA can be amplified more than 1000-fold, and a panel of tens to hundreds of cancer-related genes can be screened with a sensitivity at the single-digit molecular level.

GeneWEAVE

Series B in 2014
GeneWeave Biosciences is advancing clinical microbiology with diagnostic solutions that will enable hospitals and physicians around the world to prevent drug-resistant infections, improve antibiotic stewardship and quickly determine the optimal antibiotic therapy for critical bacterial infections. The company’s innovative and proprietary Smarticles™ technology harnesses the power of biology to enable homogeneous assays that rapidly measure bacterial drug resistance without the need for enrichment, culture, or sample preparation.

Genapsys

Series B in 2013
GenapSys, Inc. develops innovative DNA sequencing technologies for applied genomic testing and medical sequencing. The company's primary product, the GenapSys Sequencer, utilizes electrical-based detection for single nucleotide incorporations, facilitating sequencing in various laboratory settings and automating clonal amplification. GenapSys offers solutions for a wide range of applications, including research, gene editing, drug development, agriculture, forensics, and food testing. Additionally, the company seeks to collaborate with local health agencies and researchers to enhance access to sequencing insights, particularly for controlling and mitigating outbreaks. The compact and portable nature of the sequencer allows it to operate from standard power sources, making it suitable for deployment in hospitals, airports, and public transportation hubs to provide rapid results for virus samples. Founded in 2010, GenapSys is headquartered in Redwood City, California.

Genapsys

Series A in 2013
GenapSys, Inc. develops innovative DNA sequencing technologies for applied genomic testing and medical sequencing. The company's primary product, the GenapSys Sequencer, utilizes electrical-based detection for single nucleotide incorporations, facilitating sequencing in various laboratory settings and automating clonal amplification. GenapSys offers solutions for a wide range of applications, including research, gene editing, drug development, agriculture, forensics, and food testing. Additionally, the company seeks to collaborate with local health agencies and researchers to enhance access to sequencing insights, particularly for controlling and mitigating outbreaks. The compact and portable nature of the sequencer allows it to operate from standard power sources, making it suitable for deployment in hospitals, airports, and public transportation hubs to provide rapid results for virus samples. Founded in 2010, GenapSys is headquartered in Redwood City, California.

GeneWEAVE

Series A in 2012
GeneWeave Biosciences is advancing clinical microbiology with diagnostic solutions that will enable hospitals and physicians around the world to prevent drug-resistant infections, improve antibiotic stewardship and quickly determine the optimal antibiotic therapy for critical bacterial infections. The company’s innovative and proprietary Smarticles™ technology harnesses the power of biology to enable homogeneous assays that rapidly measure bacterial drug resistance without the need for enrichment, culture, or sample preparation.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.